Oxybutynin Extended Release and Tolterodine Immediate Release: A Health Economic Comparison

Clinical Drug Investigation

Volumn 24, Issue 2, 2004, Pages 81-88

  Getsios, D ^a   Caro, J J ^b,c,h   Ishak, K J ^d   El Hadi, W ^d   Payne, K ^d   O'Connel, M ^e   Albrecht, D ^e   Feng, W ^f   Dubois, D ^g  

^a Caro Research Institute   (Canada)

^b CARO RESEARCH INSTITUTE   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d Caro Research Institute   (Canada)

^e ALZA CORPORATION   (United States)

^f JOHNSON AND JOHNSON   (United States)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTINENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL LITERATURE; OVERACTIVE BLADDER; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; URINE INCONTINENCE;

EID: 1542343854     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424020-00003     Document Type: Article

References (30)

1. Abrams P, Wein AJ. Introduction to the overactive bladder: from basic science to clinical management. Urology 1997; 50 Suppl. 6A: 1-3
2. Abrams P, Blaivas JG, Stanton SL, et al. Standardization of the terminology of lower urinary tract function. Neurourol Urodyn 1988; 7: 403-27
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
4. Roe B, Doll H. Prevalence of urinary incontinence and its relationship with health status. J Clin Nurs 2000; 9: 178-88
5. Brown JS, Subak LL, Gras J, et al. Urge incontinence: the patient's perspective. J Womens Health 1998; 7: 1263-9
6. Temmi C, Haidlinger G, Schmidbauer J, et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19: 259-71
7. Stoddart H, Donavan J, Whitley E, et al. Urinary incontinence in older people in the community: a neglected problem? Br J Gen Pract 2001; 51: 548-52
8. The Continence Foundation. Making the case for investments in an integrated continence service: a sourcebook for continence services (2000). Available from URL: http://www.continence-foundation.org.uk/docs/prageb.htm [Accessed 2002 Aug 18]
9. Wagner TH, Hu T. Economic costs of urinary incontinence in 1995. Urology 1998; 5193: 356-61
10. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6 (3): 243-62
11. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med 2002; 69 (10): 761-9
12. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial for extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76: 358-63
13. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-7
14. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551-60
15. Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000; 56 Suppl. 6A: 41-9
16. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: one-year study. Int Urol Nephrol 2002; 34 (1): 43-9
17. Kobelt G, Jönsson L, Mattiason A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agents: a Markov model. Neurourol Urodyn 1998; 17: 599-611
18. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrussor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
19. Desgagné A, LeLorier J. Incontinence drug utilization patterns in Québec, Canada. Value Health 1999; 2: 452-8
20. Boone TB, Kusek JW, Nyberg LM, et al. Treatment patterns and associated symptom improvement during six months of care for overactive bladder a prospective, observational study. Clin Ther 2002; 24: 397-408
21. Netten A, Rees T, Harrison G. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury, 2001
22. Katzman-McClish D, Wyman JF, Sale PG, et al. Use and costs of incontinence pads in female study volunteers: the Continence Program for Women Research Group. J Wound Ostomy Continence Nurs 1999; 26: 207-13
23. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50 Suppl. 6A: 100-7
24. Dowell CJ, Bryant CM, Moore KH, et al. Calculating the direct costs of urinary incontinence: a new test instrument. BJU Int 1999; 83: 596-606
25. Hu T, Wagner TH. Economic considerations for overactive bladder. Am J Manag Care 2000; 6 Suppl. 11: S591-8
26. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98: 398-406
27. Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000; 13: 88-94
28. Cannon T, Chancellor MB. Pharmacotherapy of overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002; 45: 205-17
29. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clincal Effectiveness Trial (ACET). Curr Med Res Opin 2002; 18: 177-84
30. Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002; 8: 343-52